A first-in-human phase 1 study of an mKRAS peptide vaccine (mKRAS-VAX) reported safe dosing and durable immune activity in high-risk pancreatic cancer cohorts. Investigators enrolled 20 people with hereditary PDAC predisposition and radiographic pancreatic abnormalities (NCT05013216), observing grade 1–2 adverse events and mKRAS-specific T cell responses in 18/20 participants. Longitudinal TCR sequencing showed vaccine-induced mKRAS-specific clonotypes persisted for up to two years, and over a median follow-up of 16.5 months, no participants developed PDAC. The results support advancing mKRAS-targeted vaccination as a preventive interception approach aimed at precursors rather than established tumors. In parallel, Johns Hopkins researchers also reported early immunogenicity from a preventive strategy aimed at mutant KRAS variants, reinforcing momentum around shared driver targets for pancreatic interception programs.